OncoMatch/Clinical Trials/NCT05891561
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
Is NCT05891561 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pertuzumab for breast cancer.
Treatment: Pertuzumab — The investigators plan to carry out a phase II, open-label, single-arm clinical study of short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer, to explore whether 4 courses of dual HER2 blockade combined with taxanes can lead to a similar prognosis with current standard treatment, which is one-year trastuzumab monotherapy combined with chemotherapy, while reducing the adverse reactions of treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 3+ or ihc 2+ and fish-positive)
Disease stage
Required: Stage PT1
pT1, pN0, and M0 disease
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
Cannot have received: endocrine therapy
Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
Cannot have received: biotherapy
Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
Cannot have received: radiation therapy
Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
Cannot have received: neoadjuvant treatment
Receiving neoadjuvant treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05891561 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage PT1 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages